A Mechanistic Framework for in Silico Optimization of Neuroblastoma Chemo-Immunotherapy

TL;DR

This paper introduces a mathematical model to simulate and optimize combined chemo-immunotherapy strategies for neuroblastoma, aiming to improve clinical decision-making and patient outcomes.

Contribution

It presents a novel nonlinear differential equation framework that mechanistically models tumor-immune interactions and drug effects for therapy optimization.

Findings

Model accurately simulates tumor-immune dynamics.

Framework enables in silico testing of treatment regimens.

Potential to personalize therapy based on patient risk profiles.

Abstract

A critical need exists for optimal therapeutic strategies for neuroblastoma, a prevalent and often fatal pediatric solid malignancy. To address the demand for quantitative models that can guide clinical decision-making, a novel mathematical framework was developed. Combination therapies involving immunotherapy, such as Interleukin-2 (IL-2), and chemotherapy, exemplified by Cyclophosphamide, have shown significant clinical potential by enhancing anti-tumor immune responses. In this study, a nonlinear system of coupled ordinary differential equations was formulated to mechanistically describe the interactions among tumor cells, natural killer (NK) cells, and cytotoxic T lymphocytes (CTLs). The pharmacodynamic effects of both IL-2 and Cyclophosphamide on these key immune populations were explicitly incorporated, allowing for the simulation of tumor dynamics across distinct patient risk profiles. The resulting computational framework provides a robust platform for the \textit{\textbf{in silico}} \textbf{optimization} of therapeutic regimens, presenting a quantitative pathway toward the improvement of clinical outcomes for patients with neuroblastoma.